Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
BIOSPECIFICS TECHNOLOGIES CORP (BSTC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/02/2020 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...|
Docs:
|
"Amended and Restated Certificate of Incorporation of BioSpecifics Technologies Corp",
"Amended and Restated By-laws of BioSpecifics Technologies Corp",
"BioSpecifics Announces Completion of Acquisition by Endo Pharmaceuticals WILMINGTON, DE - December 2, 2020 - BioSpecifics Technologies Corp. , a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America, today announced the successful completion of its acquisition by Endo International plc for approximately $658.2 million in equity value. Endo's all-cash tender offer to acquire all of the issued and outstanding shares of BioSpecifics' common stock at a purchase price of $88.50 per share expired one minute after 11:59 p.m., New York time, on December 1, 2020. Computershare Trust Company, N.A., the depositary and paying agent for the Offer, reported that approximately 6..." |
|
| 11/09/2020 |
8-K
| Quarterly results |
| 10/19/2020 |
8-K
| Quarterly results |
| 09/14/2020 |
8-K
| Quarterly results |
| 08/31/2020 |
8-K
| Quarterly results |
| 08/11/2020 |
8-K
| Quarterly results |
| 08/10/2020 |
8-K
| Quarterly results |
| 07/20/2020 |
8-K
| Quarterly results |
| 07/14/2020 |
8-K
| Quarterly results |
| 06/15/2020 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 06/12/2020 |
8-K
| Investor presentation |
| 06/08/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/11/2020 |
8-K
| Quarterly results |
| 05/11/2020 |
8-K
| Quarterly results |
| 04/10/2020 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I... |
| 04/09/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"BioSpecifics Appoints Joseph Truitt as Interim Chief Executive Officer WILIMINGTON, DE - April 9, 2020 - BioSpecifics Technologies Corp. , a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America, today announced that the Board of Directors has appointed Joseph Truitt as interim Chief Executive Officer. He will also serve on the Company's Board of Directors. Mr. Truitt succeeds J. Kevin Buchi, who served as CEO since October 2019, and has departed the company. “We are delighted to have Joe on board and believe he will play a major role in helping to shape the future of BioSpecifics. Joe is a highly experienced biopharma executive with a strong track record of clini...",
"BioSpecifics Appoints Mike Sherman and Corey Fishman to Board of Directors WILIMINGTON, DE - April 9, 2020 - BioSpecifics Technologies Corp. , a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX ® in North America, today announced that its Board of Directors appointed Mike Sherman and Corey Fishman to serve as Independent Directors, effective immediately. Mike Sherman and Corey Fishman will both join the Board's Audit Committee, with Mr. Sherman serving as an “audit committee financial expert.” Corey Fishman will also join the Intellectual Property Committee. “Mike and Corey both bring tremendous operational and functional insight, as well as industry and business acumen, to the..." |
|
| 03/23/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 03/16/2020 |
8-K
| Quarterly results |
| 01/13/2020 |
8-K
| Investor presentation |
| 01/07/2020 |
8-K
| Termination of a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointmen... |
| 11/21/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 10/23/2019 |
8-K
| Quarterly results |
| 10/10/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/22/2019 |
8-K
| Investor presentation |
| 08/09/2019 |
8-K
| Quarterly results |
| 06/14/2019 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/23/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 05/10/2019 |
8-K
| Quarterly results |
| 04/02/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/02/2019 |
8-K
| Quarterly results |
| 03/18/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 02/28/2019 |
8-K
| Quarterly results |
| 02/21/2019 |
8-K
| Quarterly results |
| 01/24/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|